European Organisation For Research & Treatment Of Cancer
🇬🇧United Kingdom
Clinical Trials
350
Active:22
Completed:188
Trial Phases
4 Phases
Phase 1:34
Phase 2:146
Phase 3:128
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (323 trials with phase data)• Click on a phase to view related trials
Phase 2
146 (45.2%)Phase 3
128 (39.6%)Phase 1
34 (10.5%)Not Applicable
14 (4.3%)phase_2_3
1 (0.3%)A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
- First Posted Date
- 2025-11-19
- Last Posted Date
- 2025-11-19
- Target Recruit Count
- 158
- Registration Number
- NCT07234877
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Not Applicable
Not yet recruiting
- Conditions
- Non-Muscle Invasive Bladder Cancer
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 50
- Registration Number
- NCT06990061
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
Phase 1
Not yet recruiting
- Conditions
- GastroEsophageal Cancer
- Interventions
- Drug: FLOT
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-06-05
- Target Recruit Count
- 27
- Registration Number
- NCT06978062
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3
Not yet recruiting
- Conditions
- IDH-mutant Grade 2 or 3 Astrocytoma
- Interventions
- Drug: Vorasidenib Placebo
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 468
- Registration Number
- NCT06809322
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹Kepler University Hospital - Neuromed campus, Linz, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-23
- Target Recruit Count
- 48
- Registration Number
- NCT06783348
- Prev
- 1
- 2
- 3
- 4
- 5
- 70
- Next
News
No news found